Alexander M. Pyatigorsky

Alexander M. Pyatigorsky

Auto-generated profile, based on publicly available information

Alexander M. Pyatigorsky

Institute of Biomedical Chemistry

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2023 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Closed access
PDF file
APAlexander M. Pyatigorsky
Alexander M. Pyatigorsky
GBGalina E. Brkich
Galina E. Brkich
VBValery V. Beregovykh
Valery V. Beregovykh
NPNatalya Pyatigorskaya
Natalya Pyatigorskaya
ПМПятигорский Александр Михайлович
Пятигорский Александр Михайлович
ПВПятигорская Наталья Валерьевна
Пятигорская Наталья Валерьевна
Most of RD, technological and experimental works carried out in Russia result in the development of technologies with low-level readiness for possible integration into the production cycles of industrial enterprises, which, on the one hand, demonstrates a lack of understanding by developers of the requirements for the product life cycle, and on the other hand, it is the possible reason for the low share of Russia in the total world exports of high-technology goods. In order to create a scientific and technical reserve in a target time, the world practice uses the Technology Readiness Levels (TRL) scale. This approach is used in various industries and has shown the possibility to develop technologies and launch production of innovative product by a target time. However, the Ministry of Education and Science notes that this approach has not yet been used to determine the readiness levels of chemical-technological processes and pharmaceutical technologies. The article discusses main scientific problems associated with conducting a comprehensive assessment of technological readiness levels of an innovative project during the development of a pharmaceutical product, using the TRL scale and the QbD concept for a systematic and early approach to development, based on a scientific understanding of the drug life cycle processes.

26 November 2020 in Drug development & registration
Verified
Journal Article
Open access
PDF file
AMA. P. Meshkovskiy
A. P. Meshkovskiy
NPNatalya Pyatigorskaya
Natalya Pyatigorskaya
ZAZhanna Aladysheva
Zhanna Aladysheva
VBV. V. Beregovykh
V. V. Beregovykh
APA. M. Pyatigorskiy
A. M. Pyatigorskiy
VBVasiliy Belyaev
Vasiliy Belyaev
Introduction. The article is focused on differences in quality assurance-related obligations and responsibilities between Marketing Authorisation Holders (MAHs) and manufacturing authorisation holder (manufacturers) in pharmaceutical industry. In case of outsourcing and technical agreements there is a need to differentiate responsibilities related to quality assurance between the above mentioned categories.Text. The guidelines for the pharmaceutical sector of the European Union (EU) provide guidance on the responsibilities of the MAHs in relation to the GMP rules, which are scattered throughout the various chapters of the GMP and its appendices. In addition, certain provisions on this topic are contained in the EU directives. With this in mind the European Medicines Agency (EMA) issued in January 2020 a draft Reflection paper on Good manufacturing practice and Marketing Authorisation Holders. The draft clarifies that while certain activities of an MAH may be delegated to the manufacturer, MAH retains ultimate responsibility for the performance of a medicinal product, its safety, quality and efficacy. The important obligation of MAH in this context is to facilitate GMP compliance by establishing a robust two-way communication system with national competent authorities, manufacturing sites, Qualified Persons (QPs) certifying batches before release, and other interested parties. The MAH ought to communicate to manufacturing personnel, normally through QPs, production processes and related quality control procedures, including subsequent variations, described in registration dossiers.Conclusion. A general one conclusion: in view of rapid developments in the EU GMP Guide, the Eurasian Economic Union GMP requirements ought to be updated. In respect of specific responsibilities of MAH pertaining to GMP compliance the EMA draft Reflection paper merits attention as a guidance regarding separation of obligations and responsibilities between MAH and personnel of manufacturing sights.

28 August 2021 in Drug development & registration
Verified
Journal Article
Open access
PDF file
AMA. P. Meshkovskiy
A. P. Meshkovskiy
VBV. V. Beregovykh
V. V. Beregovykh
VSV. N. Shestakov
V. N. Shestakov
NPNatalya Pyatigorskaya
Natalya Pyatigorskaya
ZAZhanna Aladysheva
Zhanna Aladysheva
ENE. I. Nesterkina
E. I. Nesterkina
Introduction. The article discusses significant changes in the procedure for pharmaceutical inspection of drug manufacturers for compliance with the requirements of the rules of good manufacturing practice (GMP) of the Eurasian Economic Union (EAEU), related to restrictions due to the COVID-19 pandemic.Text. The article presents the main international guidelines describing the remote conduct of pharmaceutical inspections, which is the basis for further updating the relevant procedures in the law of the EAEU. An overview of the foreign practice of pharmaceutical inspection during the pandemic is given. In addition, the changes in the Russian regulatory approaches to control and supervision in the Russian legislation are presented.Conclusion. These data give an idea that, with considering the above, there is a need for further convergence of the requirements, the practice of conducting pharmaceutical inspections for compliance with the requirements of GMP Rules in order to harmonize the norms between Russian regulatory documents, the norms of the EAEU law and international standards. This requires the development of a dialogue with the participation of stakeholders.

7 July 2025 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Closed access
PDF file
APAlexander M. Pyatigorsky
Alexander M. Pyatigorsky
GBGalina E. Brkich
Galina E. Brkich
VBValery V. Beregovykh
Valery V. Beregovykh
NPNatalya Pyatigorskaya
Natalya Pyatigorskaya
OZOleg A. Zyryanov
Oleg A. Zyryanov
КОКузнецов Андрей Олегович
Кузнецов Андрей Олегович
With a high level of fundamental research, there is a gap between fundamental and applied research, and there is a discrepancy between the proposed research results and possible integration into industrial production cycles. Within the life cycle of a pharmaceutical product, reliable processes are the foundation for the successful operation of the enterprise. The duration of development of pharmaceutical products and projects for their implementation require the involvement of significant resources and are associated with significant risks. Starting from the earliest stages of project implementation, it is advisable to use universal, fairly simple indicators and metrics that do not depend on the type of technology and systems being developed, which allow for an adequate assessment of their current development. The production readiness level is a unified parameter used as a tool for assessing how close the results of the project’s technology readiness are to market expectations. It includes measuring the maturity of the technologies/product being developed and will allow you to quickly assess the “maturity” of the selected portfolio, assess the current and desired future of the project, improve the quality of planning, implementation and sustainability of the project.

18 June 2018 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
AMA. P. Meshkovskii
A. P. Meshkovskii
NPNatalya Pyatigorskaya
Natalya Pyatigorskaya
VBV. V. Beregovykh
V. V. Beregovykh
ZAZhanna Aladysheva
Zhanna Aladysheva
VBVasiliy Belyaev
Vasiliy Belyaev
АПАлександр Михайлович Пятигорский
Александр Михайлович Пятигорский
Introduction of amendments to the registration dossier is the responsibility of the marketing application holder (MAH). Increased knowledge on pharmaceuticals, its manufacturing and control processes can reduce the number of documents submitted to the regulatory authorities. The existing requirements establishing the procedure for the introduction of amendments differ in terms of change classification, period of notification of regulatory authorities, ways of conformity validation of pharmaceutical properties, etc. ICH proposed draft guideline Q12 «Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management» which covers the problem of harmonization of regulatory approaches to the changes provided in the «Quality» section of CTD during the commercial phase of drug life cycle. The new guideline can be considered as the continuation and elaboration of previous ICH documents. The article provides explanations on the main provisions and regulatory mechanisms introduced by the draft guideline ICH Q12: categorization of post-approval changes, established conditions, post-approval change management protocol, and drug product lifecycle management.

25 April 2017 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
NPNatalya Pyatigorskaya
Natalya Pyatigorskaya
VBV. V. Beregovykh
V. V. Beregovykh
ZAZhanna Aladysheva
Zhanna Aladysheva
VBVasiliy Belyaev
Vasiliy Belyaev
AMA. P. Meshkovskii
A. P. Meshkovskii
APA. M. Pyatigorskii
A. M. Pyatigorskii
Drugs must be produced in compliance with good manufacturing practice rules approved by an authorized federal agency. Pharmaceutical Quality System is a global requirement for development and production processes for pharmaceutical products. The article describes a variant of automated document management system of pharmaceutical manufacturer’s quality management system in accordance with current requirements of GMP. The peculiarity of the proposed system is the focuses on pharmaceutical production taking into account the characteristics and requirements for the pharmaceutical products production. All documents which are supposed to be used within the system are grouped into the four blocks: normative legal acts, core manufacturer standards according to GMP, regulatory documents, and register documents.